Hengrui Pharma’s HR19034 Eye Drops for Myopia Delay Accepted by NMPA
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that its market filing for HR19034 eye...
Gan & Lee Pharmaceuticals Doses First Patient in GZR4 Phase III Study for Diabetes
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed...
Stedical Scientific Raises RMB100M in Series B Financing for Global Expansion
Stedical Scientific, a Hangzhou-based tissue engineering and regenerative medicine company, has raised over RMB100 million...
Zelgen Biopharmaceuticals’ ZG005 Bispecific Antibody Receives NMPA Approval for Biliary Tract Cancer Trials
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received clinical trial...
Bristol-Myers Squibb Releases Five-Year Data on Sotyktu’s Long-Term Efficacy and Safety
In a recent announcement, US pharmaceutical giant Bristol-Myers Squibb (BMS, NYSE: BMY) unveiled the latest...
Wanbangde New Building Materials’ Mecobalamin Earns FDA Orphan Drug Designation for ALS
China’s Wanbangde New Building Materials Co., Ltd (SHE: 002082) announced that its mecobalamin product has...
Biokin Pharmaceutical Registers Phase III Study for BL-B01D1 in EGFR Mutant NSCLC
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has registered a Phase III study on chinadrugtrials.org.cn...
AccurEdit’s ART002 Becomes First In Vivo Gene Editing Product to Reduce LDL-C in Humans
Suzhou-based gene editing specialist AccurEdit Therapeutics announced that its in vivo gene editing product, ART002,...
Beihai Biotech Licenses Beizary to Zydus Lifesciences for US Market
China-based Zhuhai Beihai Biotech Co., Ltd announced a licensing agreement with Zydus Lifesciences, granting the...
Huadong Medicine’s HDM1005 Shows Positive Results in Phase Ia/Ib Study
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced positive results from the Phase Ia/Ib study...
PolyMed Biopharma Licenses HPB-143 to Photys Therapeutics for Global Development
PolyMed Biopharma, a Hangzhou-based developer of Proteolysis Targeting Chimera (PROTAC) drugs, has entered into a...
Samsung Bioepis’ Ospomyv and Xbryk Gain FDA Approval for RANKL Inhibitor Biosimilars
South Korea-based Samsung Bioepis Co., Ltd. announced that it has received marketing approval from the...
Kexing Biopharm’s GB05 Receives FDA Approval for Pediatric RSV Infections
China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced that it has received clinical trial approval...
Sanofi’s Merilog Biosimilar Wins FDA Approval for Diabetes Treatment
The U.S. Food and Drug Administration (FDA) has approved Sanofi-Aventis’ (EPA: SAN) Merilog, a biosimilar...
Yantai Dongcheng’s Lannacheng Bio Secures RMB150m to Advance [18F] Spiritide Study
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675)’s controlling subsidiary, Yantai Lannacheng Biotechnology Co., Ltd.,...
GSK’s Penmenvy Meningococcal Vaccine Approved by FDA for Ages 10-25
UK-based multinational GSK plc (LON: GSK) announced that it has received marketing approval from the...
3SBio and Sichuan Biokin Partner to Advance Solid Tumor Treatment in China
China-based 3SBio Inc. (HKG: 1530) has announced a strategic partnership with fellow domestic firm Sichuan...
LINDIS Biotech’s Korjuny Approved by European Commission for Malignant Ascites
Germany-based LINDIS Biotech GmbH announced that it has received market approval from the European Commission...
IASO Bio’s Fucaso NDA Accepted by Hong Kong DOH for Relapsed/Refractory Multiple Myeloma
China-based IASO Bio announced that a New Drug Application (NDA) for its BCMA-targeted chimeric antigen...
Innovent Biologics’ IBI363 Receives FDA Fast-Track Designation for sqNSCLC
China-based Innovent Biologics, Inc. (HKG: 1801) announced that it has received another fast-track designation from...